Keyword: SetPoint Medical
electroCore and UpScriptHealth will offer the former's gammaCore vagus nerve stimulation treatment through a telemedicine program.
Bioelectronic medicine developer electroCore is going public with a $78 million IPO, listing 5.2 million shares of common stock at $15.00 per share.
SetPoint Medical rounded up $30 million, which will bankroll a phase 2 trial of its bioelelectronic therapy for rheumatoid arthritis.
GE Ventures has entered a strategic alliance with the Feinstein Institute, the research arm of New York’s Northwell Health, to advance new bioelectronic therapies and diagnostics for a range of diseases.
GlaxoSmithKline-backed SetPoint Medical presented promising data from a study assessing its bioelectronic treatment for Crohn’s disease.
A trio of collaborators announced Monday clinical trial data showing that an implantable neuromodulation device improved symptoms of rheumatoid arthritis.